Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Conditions: Breast Cancer Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Low Breast Carcinoma; Advanced Breast Cancer Interventions: Drug: Patritumab deruxtecan; Drug: Olaparib Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; Daiichi Sankyo Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials